Literature DB >> 25323688

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Guido Finazzi1, Alessandra Carobbio2, Paola Guglielmelli3, Chiara Cavalloni4, Silvia Salmoiraghi1, Alessandro M Vannucchi3, Mario Cazzola4, Francesco Passamonti5, Alessandro Rambaldi1, Tiziano Barbui2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25323688     DOI： 10.1182/blood-2014-08-596676

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  27 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 3.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

4.  CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Authors:  M C Finazzi; A Carobbio; F Cervantes; I M Isola; A M Vannucchi; P Guglielmelli; A Rambaldi; G Finazzi; G Barosi; T Barbui
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

Review 5.  Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.

Authors:  Jamile M Shammo; Brady L Stein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2016-05-31

Review 7.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 8.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

Review 9.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

Review 10.  A rare CALR variant mutation and a review of CALR in essential thrombocythemia.

Authors:  Robert Diep; Ara Metjian
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.